BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 31186379)

  • 1. Long non-coding RNA AGAP2-AS1 exerts oncogenic properties in glioblastoma by epigenetically silencing TFPI2 through EZH2 and LSD1.
    Luo W; Li X; Song Z; Zhu X; Zhao S
    Aging (Albany NY); 2019 Jun; 11(11):3811-3823. PubMed ID: 31186379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulated long non-coding RNA AGAP2-AS1 represses LATS2 and KLF2 expression through interacting with EZH2 and LSD1 in non-small-cell lung cancer cells.
    Li W; Sun M; Zang C; Ma P; He J; Zhang M; Huang Z; Ding Y; Shu Y
    Cell Death Dis; 2016 May; 7(5):e2225. PubMed ID: 27195672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SOX9-activated PXN-AS1 promotes the tumorigenesis of glioblastoma by EZH2-mediated methylation of DKK1.
    Chen H; Hou G; Yang J; Chen W; Guo L; Mao Q; Ge J; Zhang X
    J Cell Mol Med; 2020 Jun; 24(11):6070-6082. PubMed ID: 32329150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AGAP2-AS1 serves as an oncogenic lncRNA and prognostic biomarker in glioblastoma multiforme.
    Tian Y; Zheng Y; Dong X
    J Cell Biochem; 2019 Jun; 120(6):9056-9062. PubMed ID: 30525219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of the long noncoding RNA FOXD2-AS1 promotes carcinogenesis by epigenetically silencing EphB3 through EZH2 and LSD1, and predicts poor prognosis in gastric cancer.
    Xu TP; Wang WY; Ma P; Shuai Y; Zhao K; Wang YF; Li W; Xia R; Chen WM; Zhang EB; Shu YQ
    Oncogene; 2018 Sep; 37(36):5020-5036. PubMed ID: 29789713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long noncoding AGAP2-AS1 is activated by SP1 and promotes cell proliferation and invasion in gastric cancer.
    Qi F; Liu X; Wu H; Yu X; Wei C; Huang X; Ji G; Nie F; Wang K
    J Hematol Oncol; 2017 Feb; 10(1):48. PubMed ID: 28209205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RREB1-induced upregulation of the lncRNA AGAP2-AS1 regulates the proliferation and migration of pancreatic cancer partly through suppressing ANKRD1 and ANGPTL4.
    Hui B; Ji H; Xu Y; Wang J; Ma Z; Zhang C; Wang K; Zhou Y
    Cell Death Dis; 2019 Feb; 10(3):207. PubMed ID: 30814490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long noncoding RNA HOXD-AS1 aggravates osteosarcoma carcinogenesis through epigenetically inhibiting p57 via EZH2.
    Gu W; Zhang E; Song L; Tu L; Wang Z; Tian F; Aikenmu K; Chu G; Zhao J
    Biomed Pharmacother; 2018 Oct; 106():890-895. PubMed ID: 30119259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Long Non-Coding RNA (lncRNA) AGAP2-AS1 is Upregulated in Ovarian Carcinoma and Negatively Regulates lncRNA MEG3.
    Chen J; Peng X; Dai Y
    Med Sci Monit; 2019 Jun; 25():4699-4704. PubMed ID: 31233485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Over-expressed lncRNA HOTAIRM1 promotes tumor growth and invasion through up-regulating HOXA1 and sequestering G9a/EZH2/Dnmts away from the HOXA1 gene in glioblastoma multiforme.
    Li Q; Dong C; Cui J; Wang Y; Hong X
    J Exp Clin Cancer Res; 2018 Oct; 37(1):265. PubMed ID: 30376874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LncRNA LEF1-AS1 silencing diminishes EZH2 expression to delay hepatocellular carcinoma development by impairing CEBPB-interaction with CDCA7.
    Gao J; Dai C; Yu X; Yin XB; Zhou F
    Cell Cycle; 2020 Apr; 19(8):870-883. PubMed ID: 32178558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOXP4-AS1 participates in the development and progression of osteosarcoma by downregulating LATS1 via binding to LSD1 and EZH2.
    Yang L; Ge D; Chen X; Qiu J; Yin Z; Zheng S; Jiang C
    Biochem Biophys Res Commun; 2018 Aug; 502(4):493-500. PubMed ID: 29859193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HOXD-AS1 confers cisplatin resistance in gastric cancer through epigenetically silencing PDCD4 via recruiting EZH2.
    Ye Y; Yang S; Han Y; Sun J; Xv L; Wu L; Ming L
    Open Biol; 2019 Sep; 9(9):190068. PubMed ID: 31551012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolomide resistance in glioblastoma cancer stem cells.
    Mazor G; Levin L; Picard D; Ahmadov U; Carén H; Borkhardt A; Reifenberger G; Leprivier G; Remke M; Rotblat B
    Cell Death Dis; 2019 Mar; 10(3):246. PubMed ID: 30867410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA FEZF1-AS1 aggravates cell proliferation and migration in glioblastoma.
    Zhou C; Jiang X; Liang A; Zhu R; Yang Y; Zhong L; Wan D
    Neurosci Lett; 2021 Nov; 764():136245. PubMed ID: 34530115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The carcinogenic complex lncRNA DUXAP8/EZH2/LSD1 accelerates the proliferation, migration and invasion of colorectal cancer.
    Gong A; Huang Z; Ge H; Cai Y; Yang C
    J BUON; 2019; 24(5):1830-1836. PubMed ID: 31786844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. lncRNA MNX1-AS1 Promotes Glioblastoma Progression Through Inhibition of miR-4443.
    Gao Y; Xu Y; Wang J; Yang X; Wen L; Feng J
    Oncol Res; 2019 Feb; 27(3):341-347. PubMed ID: 29678219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The oncogenic role of LncRNA FAM83C-AS1 in colorectal cancer development by epigenetically inhibits SEMA3F via stabilizing EZH2.
    Xue W; Wang F; Han P; Liu Y; Zhang B; Gu X; Wang Y; Li M; Zhao Y; Cui B
    Aging (Albany NY); 2020 Oct; 12(20):20396-20412. PubMed ID: 33109776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long Noncoding RNA LINC00673 Is Activated by SP1 and Exerts Oncogenic Properties by Interacting with LSD1 and EZH2 in Gastric Cancer.
    Huang M; Hou J; Wang Y; Xie M; Wei C; Nie F; Wang Z; Sun M
    Mol Ther; 2017 Apr; 25(4):1014-1026. PubMed ID: 28214253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SP1-induced upregulation of lncRNA SPRY4-IT1 exerts oncogenic properties by scaffolding EZH2/LSD1/DNMT1 and sponging miR-101-3p in cholangiocarcinoma.
    Xu Y; Yao Y; Jiang X; Zhong X; Wang Z; Li C; Kang P; Leng K; Ji D; Li Z; Huang L; Qin W; Cui Y
    J Exp Clin Cancer Res; 2018 Apr; 37(1):81. PubMed ID: 29642935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.